Highbridge Capital discloses 4.2% OnKure (OKUR) stake in Schedule 13G/A

Rhea-AI Filing Summary

OnKure Therapeutics, Inc. received an updated ownership report from Highbridge Capital Management, LLC, filed as Amendment No. 1 to a Schedule 13G. Highbridge, a Delaware investment adviser, reports beneficial ownership of 542,361 shares of OnKure’s Class A common stock.

This stake represents 4.2% of the outstanding Class A common stock, based on 12,861,672 shares outstanding as of November 5, 2025 as disclosed in OnKure’s Form 10-Q for the quarter ended September 30, 2025. Highbridge has sole voting and dispositive power over these shares and certifies they are held in the ordinary course of business, not to change or influence control of the company.

SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549

SCHEDULE 13G

UNDER THE SECURITIES EXCHANGE ACT OF 1934

(Amendment No. 1)

OnKure Therapeutics, Inc.

(Name of Issuer)

Class A Common Stock, par value $0.0001 per share

(Title of Class of Securities)

68277Q105

(CUSIP Number)

12/31/2025

(Date of Event Which Requires Filing of this Statement)

Check the appropriate box to designate the rule pursuant to which this Schedule is filed:

Rule 13d-1(b)

Rule 13d-1(c)

Rule 13d-1(d)

SCHEDULE 13G

CUSIP No. 68277Q105

1

Names of Reporting Persons

Highbridge Capital Management, LLC

2

Check the appropriate box if a member of a Group (see instructions)

(a)
(b)

3

Sec Use Only

4

Citizenship or Place of Organization

DELAWARE

Number of Shares Beneficially Owned by Each Reporting Person With:

5	Sole Voting Power 542,361.00
6	Shared Voting Power 0.00
7	Sole Dispositive Power 542,361.00
8	Shared Dispositive Power 0.00

9

Aggregate Amount Beneficially Owned by Each Reporting Person

542,361.00

10

Check box if the aggregate amount in row (9) excludes certain shares (See Instructions)

11

Percent of class represented by amount in row (9)

4.2 %

12

Type of Reporting Person (See Instructions)

IA, OO

SCHEDULE 13G

Item 1.
(a)	Name of issuer: OnKure Therapeutics, Inc.
(b)	Address of issuer's principal executive offices: 6707 Winchester Circle, #400, Boulder, CO 80301
Item 2.
(a)	Name of person filing: This statement is filed by Highbridge Capital Management, LLC ("Highbridge" or the "Reporting Person"), a Delaware limited liability company and the investment adviser to certain funds and accounts (the "Highbridge Funds"), with respect to the shares of class A common stock, par value $0.0001 per share ("Class A Common Stock"), of OnKure Therapeutics, Inc., a Delaware corporation (the "Issuer"), directly held by the Highbridge Funds. The filing of this statement should not be construed as an admission that any of the foregoing persons or the Reporting Person is, for the purposes of Section 13 of the Securities Exchange Act of 1934, the beneficial owner of the securities reported herein.
(b)	Address or principal business office or, if none, residence: The address of the business office of the Reporting Person is 390 Madison Avenue, 28th Floor, New York, NY 10017.
(c)	Citizenship: Highbridge is a Delaware limited liability company.
(d)	Title of class of securities: Class A Common Stock, par value $0.0001 per share
(e)	CUSIP No.: 68277Q105
Item 3.	If this statement is filed pursuant to §§ 240.13d-1(b) or 240.13d-2(b) or (c), check whether the person filing is a:
(a)	Broker or dealer registered under section 15 of the Act (15 U.S.C. 78o);
(b)	Bank as defined in section 3(a)(6) of the Act (15 U.S.C. 78c);
(c)	Insurance company as defined in section 3(a)(19) of the Act (15 U.S.C. 78c);
(d)	Investment company registered under section 8 of the Investment Company Act of 1940 (15 U.S.C. 80a-8);
(e)	An investment adviser in accordance with § 240.13d-1(b)(1)(ii)(E);
(f)	An employee benefit plan or endowment fund in accordance with § 240.13d-1(b)(1)(ii)(F);
(g)	A parent holding company or control person in accordance with § 240.13d-1(b)(1)(ii)(G);
(h)	A savings associations as defined in Section 3(b) of the Federal Deposit Insurance Act (12 U.S.C. 1813);
(i)	A church plan that is excluded from the definition of an investment company under section 3(c)(14) of the Investment Company Act of 1940 (15 U.S.C. 80a-3);
(j)	A non-U.S. institution in accordance with § 240.13d-1(b)(1)(ii)(J). If filing as a non-U.S. institution in accordance with § 240.13d-1(b)(1)(ii)(J), please specify the type of institution:
(k)	Group, in accordance with Rule 240.13d-1(b)(1)(ii)(K).
Item 4.	Ownership
(a)	Amount beneficially owned: The information required by Item 4(a) is set forth in Row 9 of the cover page for the Reporting Person and is incorporated herein by reference. The percentage set forth in this Schedule 13G is calculated based upon an aggregate of 12,861,672 shares of Class A Common Stock outstanding as of November 5, 2025, as reported in the Issuer's Quarterly Report on Form 10-Q for the quarterly period ended September 30, 2025, filed with the Securities and Exchange Commission on November 6, 2025.
(b)	Percent of class: 4.2%
(c)	Number of shares as to which the person has:
	(i) Sole power to vote or to direct the vote: The information required by Item 4(c)(i) is set forth in Row 5 of the cover page for the Reporting Person and is incorporated herein by reference.
	(ii) Shared power to vote or to direct the vote: The information required by Item 4(c)(ii) is set forth in Row 6 of the cover page for the Reporting Person and is incorporated herein by reference.
	(iii) Sole power to dispose or to direct the disposition of: The information required by Item 4(c)(iii) is set forth in Row 7 of the cover page for the Reporting Person and is incorporated herein by reference.
	(iv) Shared power to dispose or to direct the disposition of: The information required by Item 4(c)(iv) is set forth in Row 8 of the cover page for the Reporting Person and is incorporated herein by reference.
Item 5.	Ownership of 5 Percent or Less of a Class.
	Ownership of 5 percent or less of a class
Item 6.	Ownership of more than 5 Percent on Behalf of Another Person.
	If any other person is known to have the right to receive or the power to direct the receipt of dividends from, or the proceeds from the sale of, such securities, a statement to that effect should be included in response to this item and, if such interest relates to more than 5 percent of the class, such person should be identified. A listing of the shareholders of an investment company registered under the Investment Company Act of 1940 or the beneficiaries of employee benefit plan, pension fund or endowment fund is not required. See Item 2(a). The Highbridge Funds have the right to receive or the power to direct the receipt of dividends from, or the proceeds from the sale of, the shares of Class A Common Stock reported herein.
Item 7.	Identification and Classification of the Subsidiary Which Acquired the Security Being Reported on by the Parent Holding Company or Control Person.
	Not Applicable
Item 8.	Identification and Classification of Members of the Group.
	Not Applicable
Item 9.	Notice of Dissolution of Group.
	Not Applicable

Item 10.

Certifications:

By signing below I certify that, to the best of my knowledge and belief, the securities referred to above were acquired and are held in the ordinary course of business and were not acquired and are not held for the purpose of or with the effect of changing or influencing the control of the issuer of the securities and were not acquired and are not held in connection with or as a participant in any transaction having that purpose or effect, other than activities solely in connection with a nomination under ?? 240.14a-11.

SIGNATURE

After reasonable inquiry and to the best of my knowledge and belief, I certify that the information set forth in this statement is true, complete and correct.

Highbridge Capital Management, LLC

Signature:	/s/ Kirk Rule
Name/Title:	Kirk Rule, Executive Director
Date:	02/17/2026

FAQ

What percentage of OnKure Therapeutics (OKUR) does Highbridge Capital Management own?

Highbridge Capital Management reports beneficial ownership of 4.2% of OnKure Therapeutics’ Class A common stock. This is based on 542,361 shares held versus 12,861,672 shares outstanding as of November 5, 2025, per OnKure’s Form 10-Q.

How many OnKure Therapeutics (OKUR) shares does Highbridge Capital Management report owning?

Highbridge Capital Management reports beneficial ownership of 542,361 shares of OnKure’s Class A common stock. This figure reflects shares held for certain Highbridge-managed funds and accounts and gives Highbridge 4.2% of the class, using the company’s latest reported share count.

What is the outstanding share count used in Highbridge’s 13G/A for OnKure (OKUR)?

Highbridge calculates its ownership using 12,861,672 shares of OnKure Class A common stock outstanding as of November 5, 2025. This share count comes from OnKure’s Quarterly Report on Form 10-Q for the period ended September 30, 2025.

Does Highbridge Capital Management seek control of OnKure Therapeutics (OKUR)?

Highbridge certifies its OnKure shares were acquired and are held in the ordinary course of business. It states they were not acquired for the purpose of changing or influencing control of OnKure and are not part of any such control-related transaction.

What voting and dispositive powers does Highbridge have over its OnKure (OKUR) shares?

Highbridge reports sole voting power and sole dispositive power over 542,361 shares of OnKure Class A common stock. It reports no shared voting or dispositive power, meaning decisions over these shares rest solely with Highbridge on behalf of its funds.

Why did Highbridge file Amendment No. 1 to its Schedule 13G on OnKure (OKUR)?

Amendment No. 1 updates Highbridge’s beneficial ownership information in OnKure. As of the event date December 31, 2025, Highbridge reports holding 542,361 shares, or 4.2% of the class, confirming continued passive, ordinary-course ownership below the 5% threshold.